Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51


Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics.

Sorolla A, Wang E, Golden E, Duffy C, Henriques ST, Redfern AD, Blancafort P.

Oncogene. 2019 Oct 21. doi: 10.1038/s41388-019-1056-3. [Epub ahead of print] Review.


Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers.

Kretzmann JA, Evans CW, Moses C, Sorolla A, Kretzmann AL, Wang E, Ho D, Hackett MJ, Dessauvagie BF, Smith NM, Redfern AD, Waryah C, Norret M, Iyer KS, Blancafort P.

Chem Sci. 2019 Jun 27;10(33):7718-7727. doi: 10.1039/c9sc01432b. eCollection 2019 Sep 7.


Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides.

Sorolla A, Wang E, Clemons TD, Evans CW, Plani-Lam JH, Golden E, Dessauvagie B, Redfern AD, Swaminathan-Iyer K, Blancafort P.

Nanomedicine. 2019 Aug;20:102003. doi: 10.1016/j.nano.2019.04.006. Epub 2019 May 2.


Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System.

Moses C, Nugent F, Waryah CB, Garcia-Bloj B, Harvey AR, Blancafort P.

Mol Ther Nucleic Acids. 2019 Mar 1;14:287-300. doi: 10.1016/j.omtn.2018.12.003. Epub 2018 Dec 14.


Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells.

Shrestha S, Sorolla A, Fromont J, Blancafort P, Flematti GR.

Mar Drugs. 2018 Oct 1;16(10). pii: E361. doi: 10.3390/md16100361.


Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.

Wang E, Sorolla A, Cunningham PT, Bogdawa HM, Beck S, Golden E, Dewhurst RE, Florez L, Cruickshank MN, Hoffmann K, Hopkins RM, Kim J, Woo AJ, Watt PM, Blancafort P.

Oncogene. 2019 Jan;38(1):140-150. doi: 10.1038/s41388-018-0421-y. Epub 2018 Aug 3.


Atomistic molecular dynamics simulations of bioactive engrailed 1 interference peptides (EN1-iPeps).

Gandhi NS, Blancafort P, Mancera RL.

Oncotarget. 2018 Apr 27;9(32):22383-22397. doi: 10.18632/oncotarget.25025. eCollection 2018 Apr 27.


Non-viral Methodology for Efficient Co-transfection.

Kretzmann JA, Evans CW, Norret M, Blancafort P, Swaminathan Iyer K.

Methods Mol Biol. 2018;1767:241-254. doi: 10.1007/978-1-4939-7774-1_13.


Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing.

Waryah CB, Moses C, Arooj M, Blancafort P.

Methods Mol Biol. 2018;1767:19-63. doi: 10.1007/978-1-4939-7774-1_2. Review.


Hallmarks of cancer: The CRISPR generation.

Moses C, Garcia-Bloj B, Harvey AR, Blancafort P.

Eur J Cancer. 2018 Apr;93:10-18. doi: 10.1016/j.ejca.2018.01.002. Epub 2018 Feb 9. Review.


Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells.

Shrestha S, Sorolla A, Fromont J, Blancafort P, Flematti GR.

Mar Drugs. 2018 Feb 8;16(2). pii: E53. doi: 10.3390/md16020053.


Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA.

Kretzmann JA, Ho D, Evans CW, Plani-Lam JHC, Garcia-Bloj B, Mohamed AE, O'Mara ML, Ford E, Tan DEK, Lister R, Blancafort P, Norret M, Iyer KS.

Chem Sci. 2017 Apr 1;8(4):2923-2930. doi: 10.1039/c7sc00097a. Epub 2017 Jan 27.


Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.

Garcia-Bloj B, Moses C, Sgro A, Plani-Lam J, Arooj M, Duffy C, Thiruvengadam S, Sorolla A, Rashwan R, Mancera RL, Leisewitz A, Swift-Scanlan T, Corvalan AH, Blancafort P.

Oncotarget. 2016 Sep 13;7(37):60535-60554. doi: 10.18632/oncotarget.11142.


Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide.

Sorolla A, Ho D, Wang E, Evans CW, Ormonde CF, Rashwan R, Singh R, Iyer KS, Blancafort P.

Nanoscale. 2016 Apr 28;8(17):9343-53. doi: 10.1039/c5nr08331a.


Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation.

Huisman C, van der Wijst MG, Schokker M, Blancafort P, Terpstra MM, Kok K, van der Zee AG, Schuuring E, Wisman GB, Rots MG.

Mol Ther. 2016 Mar;24(3):536-47. doi: 10.1038/mt.2015.226. Epub 2015 Dec 21.


The CRISPR road: from bench to bedside on an RNA-guided path.

Garcia-Bloj B, Moses C, Blancafort P.

Ann Transl Med. 2015 Aug;3(13):174. doi: 10.3978/j.issn.2305-5839.2015.07.20. No abstract available.


Gene expression in breastmilk cells is associated with maternal and infant characteristics.

Twigger AJ, Hepworth AR, Lai CT, Chetwynd E, Stuebe AM, Blancafort P, Hartmann PE, Geddes DT, Kakulas F.

Sci Rep. 2015 Aug 10;5:12933. doi: 10.1038/srep12933.


Epigenome engineering in cancer: fairytale or a realistic path to the clinic?

Falahi F, Sgro A, Blancafort P.

Front Oncol. 2015 Feb 6;5:22. doi: 10.3389/fonc.2015.00022. eCollection 2015. Review.


Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer.

Stolzenburg S, Beltran AS, Swift-Scanlan T, Rivenbark AG, Rashwan R, Blancafort P.

Oncogene. 2015 Oct;34(43):5427-35. doi: 10.1038/onc.2014.470. Epub 2015 Feb 16.


Long live the stem cell: the use of stem cells isolated from post mortem tissues for translational strategies.

Hodgetts SI, Stagg K, Sturm M, Edel M, Blancafort P.

Int J Biochem Cell Biol. 2014 Nov;56:74-81. doi: 10.1016/j.biocel.2014.09.028. Epub 2014 Oct 7. Review.


Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation.

Grimmer MR, Stolzenburg S, Ford E, Lister R, Blancafort P, Farnham PJ.

Nucleic Acids Res. 2014;42(16):10856-68. doi: 10.1093/nar/gku708. Epub 2014 Aug 13.


Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function.

Beltran AS, Graves LM, Blancafort P.

Oncogene. 2014 Sep 25;33(39):4767-77. doi: 10.1038/onc.2013.422. Epub 2013 Oct 21.


Cisplatin induces differentiation of breast cancer cells.

Prabhakaran P, Hassiotou F, Blancafort P, Filgueira L.

Front Oncol. 2013 Jun 3;3:134. doi: 10.3389/fonc.2013.00134. eCollection 2013.


Expression of the Pluripotency Transcription Factor OCT4 in the Normal and Aberrant Mammary Gland.

Hassiotou F, Hepworth AR, Beltran AS, Mathews MM, Stuebe AM, Hartmann PE, Filgueira L, Blancafort P.

Front Oncol. 2013 Apr 11;3:79. doi: 10.3389/fonc.2013.00079. eCollection 2013.


Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer.

van der Gun BT, Huisman C, Stolzenburg S, Kazemier HG, Ruiters MH, Blancafort P, Rots MG.

Br J Cancer. 2013 Mar 5;108(4):881-6. doi: 10.1038/bjc.2013.45. Epub 2013 Feb 12.


Breaking through an epigenetic wall: re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors.

Juárez-Moreno K, Erices R, Beltran AS, Stolzenburg S, Cuello-Fredes M, Owen GI, Qian H, Blancafort P.

Epigenetics. 2013 Feb;8(2):164-76. doi: 10.4161/epi.23503. Epub 2013 Jan 11.


Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.

Wang Y, Su HH, Yang Y, Hu Y, Zhang L, Blancafort P, Huang L.

Mol Ther. 2013 Feb;21(2):358-67. doi: 10.1038/mt.2012.250. Epub 2012 Dec 11.


Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules.

Blancafort P, Jin J, Frye S.

Mol Pharmacol. 2013 Mar;83(3):563-76. doi: 10.1124/mol.112.080697. Epub 2012 Nov 13. Review.


Breastmilk is a novel source of stem cells with multilineage differentiation potential.

Hassiotou F, Beltran A, Chetwynd E, Stuebe AM, Twigger AJ, Metzger P, Trengove N, Lai CT, Filgueira L, Blancafort P, Hartmann PE.

Stem Cells. 2012 Oct;30(10):2164-74. doi: 10.1002/stem.1188.


Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors.

Lara H, Wang Y, Beltran AS, Juárez-Moreno K, Yuan X, Kato S, Leisewitz AV, Cuello Fredes M, Licea AF, Connolly DC, Huang L, Blancafort P.

J Biol Chem. 2012 Aug 24;287(35):29873-86. doi: 10.1074/jbc.M112.360768. Epub 2012 Jul 10.


Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer.

Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, Strahl BD, Blancafort P.

Nucleic Acids Res. 2012 Aug;40(14):6725-40. Epub 2012 May 4.


Epigenetic reprogramming of cancer cells via targeted DNA methylation.

Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD, Blancafort P.

Epigenetics. 2012 Apr;7(4):350-60. doi: 10.4161/epi.19507. Epub 2012 Apr 1.


Sequence-specific biosensors report drug-induced changes in epigenetic silencing in living cells.

Huang X, Narayanaswamy R, Fenn K, Szpakowski S, Sasaki C, Costa J, Blancafort P, Lizardi PM.

DNA Cell Biol. 2012 Oct;31 Suppl 1:S2-10. doi: 10.1089/dna.2011.1537. Epub 2012 Feb 7.


Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor.

Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, Zimmerman E, Graves LM, Blancafort P.

Breast Cancer Res. 2011 Sep 27;13(5):R94. doi: 10.1186/bcr3019.


Suppression of breast tumor growth and metastasis by an engineered transcription factor.

Beltran AS, Russo A, Lara H, Fan C, Lizardi PM, Blancafort P.

PLoS One. 2011;6(9):e24595. doi: 10.1371/journal.pone.0024595. Epub 2011 Sep 13.


Remodeling genomes with artificial transcription factors (ATFs).

Beltran AS, Blancafort P.

Methods Mol Biol. 2010;649:163-82. doi: 10.1007/978-1-60761-753-2_10.


Rational design, selection and specificity of artificial transcription factors (ATFs): the influence of chromatin in target gene regulation.

Blancafort P, Beltran AS.

Comb Chem High Throughput Screen. 2008 Feb;11(2):146-58. Review.


Modulation of drug resistance by artificial transcription factors.

Blancafort P, Tschan MP, Bergquist S, Guthy D, Brachat A, Sheeter DA, Torbett BE, Erdmann D, Barbas CF 3rd.

Mol Cancer Ther. 2008 Mar;7(3):688-97. doi: 10.1158/1535-7163.MCT-07-0381. Epub 2008 Mar 4.


Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors.

Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, Blancafort P.

Oncogene. 2007 Apr 26;26(19):2791-8. Epub 2006 Oct 23.


Interrogating genomes with combinatorial artificial transcription factor libraries: asking zinc finger questions.

Beltran A, Liu Y, Parikh S, Temple B, Blancafort P.

Assay Drug Dev Technol. 2006 Jun;4(3):317-31. Review.


Development of zinc finger domains for recognition of the 5'-CNN-3' family DNA sequences and their use in the construction of artificial transcription factors.

Dreier B, Fuller RP, Segal DJ, Lund CV, Blancafort P, Huber A, Koksch B, Barbas CF 3rd.

J Biol Chem. 2005 Oct 21;280(42):35588-97. Epub 2005 Aug 17.


Genetic reprogramming of tumor cells by zinc finger transcription factors.

Blancafort P, Chen EI, Gonzalez B, Bergquist S, Zijlstra A, Guthy D, Brachat A, Brakenhoff RH, Quigley JP, Erdmann D, Barbas CF 3rd.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11716-21. Epub 2005 Aug 4.


Designing transcription factor architectures for drug discovery.

Blancafort P, Segal DJ, Barbas CF 3rd.

Mol Pharmacol. 2004 Dec;66(6):1361-71. Epub 2004 Aug 31. Review.


Promoter-targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation.

Lund CV, Blancafort P, Popkov M, Barbas CF 3rd.

J Mol Biol. 2004 Jul 9;340(3):599-613.


Scanning the human genome with combinatorial transcription factor libraries.

Blancafort P, Magnenat L, Barbas CF 3rd.

Nat Biotechnol. 2003 Mar;21(3):269-74. Epub 2003 Feb 18.


Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins.

Segal DJ, Beerli RR, Blancafort P, Dreier B, Effertz K, Huber A, Koksch B, Lund CV, Magnenat L, Valente D, Barbas CF 3rd.

Biochemistry. 2003 Feb 25;42(7):2137-48.


The recognition of a noncanonical RNA base pair by a zinc finger protein.

Blancafort P, Steinberg SV, Paquin B, Klinck R, Scott JK, Cedergren R.

Chem Biol. 1999 Aug;6(8):585-97.


Supplemental Content

Loading ...
Support Center